Adam Myers to spearhead Cleveland Clinic’s population health initiative

Adam Myers, MD, MHCM, FACHE, has joined the Cleveland Clinic as the director of community care and the chief of population health. He will lead Cleveland Clinic's new approach to managing care that will “proactively address the health needs of populations.”

Using customized registries and reports, Cleveland Clinic providers will be able to determine if patients are attending health appointments. Any member of the patient care team can connect with consenting patients to discuss their current health status and determine next steps.

“We look forward to welcoming Dr. Myers to lead Cleveland Clinic Community Care, a model that was launched in January after a year of thoughtful development,” said Herb Wiedemann, MD, Cleveland Clinic Chief of Staff, in a prepared statement. “While we already have made great strides in reorganizing our primary care practices to deliver on the promise of population health, which is to enhance health and value for the populations we serve, we are confident Dr. Myers will help us extend the model further.”

Myers will direct a team comprising physicians and advanced practice providers from various service lines including internal medicine, geriatrics and pediatrics. He brings with him population health leadership experience from the Texas Health Physicians Group/Enterprise, Texas Southwestern Medical Center, Methodist Health System and the American Hospital Association.

""

As a senior news writer for TriMed, Subrata covers cardiology, clinical innovation and healthcare business. She has a master’s degree in communication management and 12 years of experience in journalism and public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.